Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Randy Prescilla"'
Autor:
Amy S. Paller, Jonathan I. Silverberg, Mercedes E. Gonzalez, Lynda C. Schneider, Robert Sidbury, Zhen Chen, Ashish Bansal, Zhixiao Wang, Randy Prescilla
Publikováno v:
Frontiers in Pediatrics, Vol 12 (2024)
BackgroundModerate-to-severe atopic dermatitis (AD) often has a profound impact on the quality of life of young children and their caregivers. One of the most burdensome symptoms reported by patients is skin pain.MethodsThis post hoc analysis focuses
Externí odkaz:
https://doaj.org/article/8ddb5c6e71134ef9bcfe2f99ceb78773
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in
Externí odkaz:
https://doaj.org/article/bccccf39e2c04fe797d29dddc1d7b23d
Autor:
Michael J. Cork, Diamant Thaçi, Lawrence F. Eichenfield, Peter D. Arkwright, Zhen Chen, Ryan B. Thomas, Matthew P. Kosloski, Ariane Dubost-Brama, Randy Prescilla, Ashish Bansal, Noah A. Levit
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 11, Pp 2697-2719 (2023)
Abstract Background For children aged 6–11 years with uncontrolled severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical benefit compared with placebo with an acceptable safety profile. However, longer
Externí odkaz:
https://doaj.org/article/4dab87121bb04ebfa5a3e58c15eea599
Autor:
Elaine C. Siegfried, Eric L. Simpson, Michael J. Cork, Peter D. Arkwright, Lara Wine Lee, Zhen Chen, Randy Prescilla, Ashish Bansal, Noah A. Levit, Ainara Rodríguez Marco
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 9, Pp 1987-2000 (2023)
Abstract Introduction Atopic dermatitis (AD) is heterogeneous in distribution pattern and clinical features. This analysis assessed the effect of dupilumab on the extent and severity of AD across various signs (erythema, edema/papulation, excoriation
Externí odkaz:
https://doaj.org/article/7f9dd1149078422ab5b7d8705d2ca580
Autor:
Amy S. Paller, Stephan Weidinger, Korey Capozza, Andrew E. Pink, Mark Tang, Xavier Guillaume, Amy Praestgaard, Marjorie Leclerc, Chien-Chia Chuang, Ryan B. Thomas, Randy Prescilla
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 4, Pp 961-980 (2023)
Abstract Introduction Atopic dermatitis (AD)—a chronic inflammatory skin disease characterized by intense itching—can have a detrimental impact on quality of life (QoL). We report results of a quantitative assessment of pediatric patient, caregiv
Externí odkaz:
https://doaj.org/article/557d70e4334b4f51a68d27c516e8faa1
Autor:
Elaine C Siegfried, Lara Wine Lee, Jonathan M Spergel, Sumeet Uppal, Anna Coleman, Brad Shumel, Randy Prescilla, Ashish Bansal, Sonya L Cyr
Publikováno v:
British Journal of Dermatology. 188
In patients with atopic dermatitis (AD), it is unknown whether suppression of dysregulated type 2 immune cytokines, interleukin-4 and interleukin-13, with dupilumab impacts the risk of viral infections following live attenuated vaccination. Current m
Publikováno v:
British Journal of Dermatology. 188
Continuous use of several traditional systemic atopic dermatitis (AD) treatments in pediatric patients is not recommended due to safety concerns and lack of long-term efficacy data. Children aged 6 months to 5 years with moderate-to-severe AD who had
Autor:
Amy S Paller, Andreas Pinter, Lara Wine Lee, Roland Aschoff, Jacek Zdybski, Christina Schnopp, Amy Praestgaard, Ashish Bansal, Brad Shumel, Randy Prescilla, Mike Bastian
Publikováno v:
British Journal of Dermatology. 188
There are limited approved systemic treatment options for children with atopic dermatitis (AD). Dupilumab is now approved in the United States for patients 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately c
Autor:
Amy S Paller, Andreas Wollenberg, Elaine C Siegfried, Mercedes E Gonzalez, Benjamin Lockshin, Faisal A Khokhar, Zhen Chen, Tayler Gonzalez, Randy Prescilla
Publikováno v:
British Journal of Dermatology. 188
Many systemic therapies used for moderate-to-severe atopic dermatitis (AD) have immunosuppressive properties and necessitate laboratory screening and monitoring, adding to the treatment burden. Previous dupilumab studies in adults, adolescents and ch
Autor:
Amy S. Paller, Elaine C. Siegfried, Michael J. Cork, Andreas Wollenberg, Peter D. Arkwright, Mercedes E. Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A. Levit, Randy Prescilla
Publikováno v:
Arkwright, P 2023, ' Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis ', Pediatric Drugs . https://doi.org/10.1007/s40272-022-00553-8
Background and ObjectivePrevious studies of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents, and severe atopic dermatitis in children aged 6 to < 12 years demonstrate no clinically important changes in la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0aafdd51fcb5f43b3726d128ab1ad54
https://research.manchester.ac.uk/en/publications/18e6b645-b1eb-4e1b-a228-cdaeca3c04b3
https://research.manchester.ac.uk/en/publications/18e6b645-b1eb-4e1b-a228-cdaeca3c04b3